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Hematopoietic stem cells can be procured from unrelated donors via either the bone marrow (BM) aspiration
or peripheral blood stem cell (PBSC) collection methods. There is no evidence from prospective randomized
trials in the unrelated donor setting about the relative health-related quality-of-life (HRQoL) beneﬁts/costs to
donors. The goals of this prospective longitudinal investigation were to describe and compare the donation-
related HRQoL experiences of 332 BM and PBSC donors. Donors were interviewed before donation, 48 hours
after donation, weekly until fully recovered, and at 6 and 12 months after donation. Before donation, BM
donors had lower confusion, fewer concerns, and were more prepared for donation. Shortly after donation,
BM donors reported more physical side effects. BM donors also reported more donation-related impact on
their social activities. However, BM donors reported somewhat better psychological status and were more
likely to indicate that the donation made their lives more meaningful. There were virtually no longer term
differences in the experiences of the 2 donor groups, including no recovery time difference beginning
3 weeks after donation. Although BM donors may experience the process as more physically stressful and
more psychologically beneﬁcial in the short term, the longer term HRQoL consequences of BM and PBSC
donors are similar.
Published by Elsevier Inc. on behalf of American Society for Blood and Marrow Transplantation.INTRODUCTION
Hematopoietic stem cell (HSC) transplantation is
increasingly used to treat leukemia or other blood-related
diseases for which other forms of therapy are ineffective or
would be less effective. Because a minority of patients
requiring transplants can ﬁnd a matched related HSC donor,
approximately 14,000 patients each year search interna-
tional registries for unrelated donors [1].
When unrelated potential donors preliminarily match a
patient, they are contacted to undergo additional testing to
conﬁrm eligibility. If selected, they then donate via either the
traditional bone marrow (BM) aspiration procedure or thety of Life ancillary study were made by
ervices Administration contract no.
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Services, Health Resources and Services
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13.10.024more recent peripheral blood stem cell (PBSC) procedure.
Donors who donate BM undergo general/regional anes-
thesia, and HSCs are collected percutaneously from the
posterior iliac crests of the pelvis. Donors who donate PBSCs
receive a 5-day course of recombinant human granulocyte
colony-stimulating factor (rhGCSF), after which HSCs are
collected from the peripheral blood on 1 or 2 consecutive
days in 4- to 5-hour apheresis sessions.
Rates of adverse events in donation vary across in-
vestigations, primarily depending on whether or not both
related and unrelated donors are included [2,3]. Strict
guidelines mean that unrelated donors are, on average,
younger and healthier than their related donor counterparts
and, therefore, experience fewer adverse events. Published
data indicate that for unrelated donors, both BM and PBSC
donation are generally safe with a low incidence of serious
adverse eventsd1.34% in BM donors and .6% in PBSC donors
[4-8]. Therefore, the decision about which type of product is
requested is left to the transplantation physician managing
the patient. In recent years, the use of PBSC donation has
increased because of more rapid hematopoietic engraftment,
more reliable engraftment when reduced-intensity condi-
tioning is used, and the potential for greater graft versusSociety for Blood and Marrow Transplantation.
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PBSC versus BM. PBSC now accounts for 75% of all adult-
derived unrelated donations (National Marrow Donor Pro-
gram statistics) [9]. Until recently, there was no evidence
from prospective randomized trials in the unrelated donor
setting that 1 product or the other conferred a survival
advantage to recipients, nor was there conclusive evidence
about the relative health-related quality-of-life (HRQoL)
beneﬁts/costs to donors.
There have been several investigations of donor experi-
ences of BM versus PBSC donation. These investigations
focused on the physical experience and physical side-effects
of the donation process and found that (1) both BM and PBSC
donors experience side effects of the donation process, most
commonly pain and fatigue [10]; (2) BM donors have a longer
recovery time than do PBSC donors [10,11]; and (3) serious
adverse events are very rare, but more common in BM do-
nors [10]. Other ﬁndingsweremixed, including the questions
of whether BM or PBSC donors experience similar pain
severity and duration [10,11], overall symptom burden
[10,12], and emotional stress related to donation [10,13].
Many of these investigations were limited by small numbers
of donors, inclusion of donors only from a single transplant
center, nonrandomized designs, and/or exclusive focus on
physical rather than psychosocial factors.
To address questions about the relative advantages/dis-
advantages to both patients and donors of the 2 HSC
collection and transplantation procedures, the Blood and
Marrow Transplant Clinical Trials Network recently
completed a phase III trial randomizing patients to receive
either marrow or PBSC grafts. Findings for transplant re-
cipients indicated that there were no statistically signiﬁcant
differences in patient survival at 2 years between the 2
procedures [14]. Here, we present ﬁndings from a planned
subanalysis of the trial, examining the physical and psycho-
social experiences of the 2 types of donors. The goals were to
describe the donation-related experiences of BM and PBSC
donors and to determine whether there were group differ-
ences before donation and at and multiple points after
donation.
MATERIALS AND METHODS
Human Subjects Research Protection
This investigation was approved by the institutional review boards at
the University of Pittsburgh, the National Marrow Donor Program (NMDP),
and individual donor centers. All participants signed informed consent
before completing the study interview.
Participants and Study Design
Our investigation was a prespeciﬁed subgroup analysis of Blood and
Marrow Transplant Clinical Trials Network protocol 0201 (ClinicalTrials.gov
Identiﬁer: NCT00075816). The prospective, longitudinal investigation
included NMDP donors enrolled in the parent randomized clinical trial (RCT)
and randomized to donate PBSC or BM from March 2004 through
October 2009.
To be eligible, potential participants were required to (1) meet the
standard NMDP requirements for donation; (2) be selected for participation
in the RCT; (3) consent to participate in both the RCT and the donor sub-
study; and (4) be enrolled in the parent RCT. Potential participants were
excluded from the study if they did not read, write, and speak English; were
unable to complete a telephone interview because of cognitive or linguistic
difﬁculties; or if they did not have access to a telephone. Department of
Defense donors (after February 6, 2007) and German Registry donors were
also excluded from the donor substudy on the basis of logistical issues and
language respectively.
NMDP donor center coordinators obtained consent from the partici-
pants for the study and passed contact information of enrolled donors to
University of Pittsburgh staff. Interviewers from the University of Pittsburgh
contacted participants by phone to complete data collection. Within
4 weeks before marrow donation or initiation of rhGCSF administration forPBSC donors, participants completed a baseline interview. PBSC donors only
were interviewed on day 4 of rhGCSF administration to assess current pain
levels. All donors were interviewed again 48 hours after donation and
weekly until symptom free for 3 consecutive weeks. Participants were also
interviewed 6 and 12 months after donation. The baseline and 48 hours
postdonation interviews required 20 minutes to completedother in-
terviews required 15 minutes. A computer-assisted telephone interview
system was used to collect and enter interview data. Data were stored on a
secure server in a proprietary data ﬁle.
Study Measures
Four categories of participant characteristics were assessed: (1) socio-
demographic, (2) physical status, (3) psychological status, and (4)
donation-related characteristics. Measureswere previously validated scales/
items with established measurement properties either created for, or used
in, other donation-related settings. Donor height and weight and experience
of an adverse event (AE) or a serious adverse event (SAE) were collected
directly from the NMDP.
Socio-demographic characteristics
Age, sex, marital status, education level, employment status, and race
were assessed.
Physical status
Overall physical status was assessed with the physical status summary
scale of the SF-8 [14]. Scores range from 0 to 100, with higher scores indi-
cating better physical health. Current symptoms assessed as present/absent
in the past 48 hours included tiredness, muscle aches, problems sleeping,
bone pain, light headedness, pain where the needles were inserted, difﬁ-
culty walking, bleeding, nausea, infection, chills, and fainting [12]. Current
pain was assessed with 4 items indicating highest pain intensity, average
pain, amount of pain, and effect of pain on sleep during the past 48 hours.
Pain was rated on a scale from 0 to 10 with a higher score indicating more
pain. A composite pain index was also created by averaging the 4-item
scores [10].
Psychological status
Overall psychological status was assessed with the psychological status
summary scale of the Short Form (SF)-8 [15]. Scores range from0 to 100with
higher scores indicating better psychological health. Mood disturbance was
assessed with the Proﬁle of Mood States-Short Form (POMS-SF) [16]. The
POMS-SF is a 30-item measure that produces scores on 6 subscales:
depression, tension-anxiety, anger, confusion, fatigue, and vitality (range,
0 to 4) and an overall distress score (calculated as the sum of the means of
each of the POMS-SF subscales; range 0 to 24) [17]. For all POMS scales other
than vitality, a higher score indicates greater distressdhigher vitality scores
indicate more vitality.
Donation-related characteristics
At the predonation interview, interactions with others were assessed
with 4 items, asking whether donors consulted family/friends or pro-
fessionals about donation and whether they had been encouraged/
discouraged from donating (yes or no) [18,19]. Concerns about donation
were assessed with 13 concerns in 3 categoriesdmedical, work/family, and
other (yes or no) [18-20]. Preparedness for donation was assessed with 3
items, asking whether donors felt informed about donation (1 ¼ not at all,
4 ¼ very well), prepared for donation (no, mostly, totally) and whether they
felt they needed more information before donating (1 ¼ need much more
information, 4 ¼ do not need any more information) [12]. All items were
dichotomized to “totally prepared/informed” versus other categories. Health
concerns were assessed with 2 items asking about worry about longer term
health impact of donation (1 ¼ deﬁnitely will have impact, 4 ¼ deﬁnitely
will not have impact) and worry about never feeling 100% well again after
donation (1 ¼ very often, 4 ¼ never) [12]. The 2 items were dichotomized to
lowest concern about health impact (eg, deﬁnitely will not have impact)
versus other categories. Satisfaction with the donation decisionwas assessed
with 2 items asking about overall satisfaction with the decision (1 ¼ not at
all, 4¼ extremely) andwhether theywould volunteer and/or donate again if
asked (1 ¼ no, 4 ¼ deﬁnitely), and an additional 4 items at postdonation
time points asking whether donors would encourage others to donate
(1 ¼ discourage strongly, 5 ¼ encourage strongly), felt like a better person
after donating (1¼ not at all, 3¼ a lot), felt proud about donating (1¼ not at
all, 3 ¼ very), and whether donating made their life seem more meaningful
(1 ¼ not at all, 4 ¼ very much). All items were dichotomized to highest
satisfaction (eg, extremely satisﬁed) versus other categories [21]. At
48 hours after donation only, the social impact of donationwas assessed with
6 items asking whether work, school, and/or leisure activities were affected
by donation, and whether the donor needed to make travel, childcare,
ﬁnancial, or home care arrangements (yes or no) [10]. Donation experience
Table 1
Interview Completion Rates at Cross-sectional Time Points
Time Point Interviews Completed
at Time Point
Percent of Total
(N ¼ 332)
Before donation 331 99%
48 hours post donation 273 82%
Weekly until fully recovered 318 96%
6 months post donation 294 89%
12 months post donation 288 87%
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donation (1 ¼ not at all stressful, 4 ¼ very stressful) [12]. Items were
dichotomized to no stress versus any stress. Recipient-related variables
included whether the donor knew the recipient’s health status (yes or no),
frequency of thoughts about the recipient (once per/day versus all other
frequencies), whether they felt they had a special bond with (not at all
versus a little, somewhat, and very much) and were worried about the
recipient (very and pretty versus not very and not at all) [12]. Postdonation
recovery was evaluated in 2 ways. Donors were assessed weekly after
donation for the presence or absence of 12 key symptoms [12] and were
considered fully recovered after 3 consecutive symptom-free weeks.
Symptoms were assessed without asking donors to make an attribution of
the symptoms speciﬁcally to donation. This is a conservative deﬁnition of
recovery and necessarily means that no donor can be recognized as fully
recovered until at least 3 weeks post donation. Recovery was calculated both
as the proportion of donors recovered versus not at 6 and 12 months and as
a continuous variable (week of full recovery) across the 52 weeks following
donation.
Clinical
Donor height (cm) and weight (kg) and the presence or absence of an AE
or SAE were assessed.
Statistical Analysis
Data were cleaned and exported from the computer-assisted telephone
interview system to PASW Statistic 18, Release Version 18.0.3 (IBM Corpo-
ration, Somer, NY) for analysis. Cross-sectional differences in donor HRQoL
by donation type at each key time point were examined using odds ratios for
categorical variables and t-tests for continuous variables. To account for
multiple comparisons, we applied the Holm-Bonferroni correction to each of
the 4 classes of variables separately for each time point [22]. When the
correction was applied, comparisons signiﬁcant at .001 remained signiﬁ-
cant, but thosewith P values>.001 no longer reached statistical signiﬁcance.
In the tables, we noted which comparisons were signiﬁcant at .05, .01, and
.001. In the text, we refer to comparisons with differences of P  .001 as
signiﬁcant and those with differences of P  .05 and P  .01 as marginally
signiﬁcant.
To examine longitudinal differences in physical and mental health (SF-8
physical and mental health summary scores) by donation type, we used
linear mixed models analyses. Main effects for donation type and time and
the donation type by time interaction were examined. We used Kaplan
Meier (log rank chi-square) analyses to examine potential differences in
recovery time by donation type using week of full recovery as the primary
outcome.
RESULTS
Participants
Of the 551 donors who participated in the parent RCT, 335
were eligible for the substudy. The primary reason for inel-
igibility was registration in the Department of Defense
(n ¼ 25) or German registries (n ¼ 154). An additional 34
potential donors were ineligible because of issues related to
the recipient or because they were non-English speaking.
Three donors declined participation. A total of 332 donors
contributed data.
Table 1 lists interview completion rates by cross-sectional
time point. A total panel of 236 (71%) completed the baseline,
48 hours postdonation, and 6- and 12-month postdonation
interviews. There were no differences between panel and
nonpanel members by gender, race, age, marital status, or
employment status.
Predonation Characteristics
The predonation interview was completed by BM and
PBSC donors an average of 10.6 and 11.5 days respectively
before donation (7 and 6 days, respectively).
The majority of participants were in their 30s, white,
male, married, and employeddabout one half had
completed a bachelor’s degree (Table 2). There were no
group differences in demographic characteristics, clinical
variables, physical/psychological status (although BM donors
were marginally more likely to report infection and lesslikely to report confusion), or any of the variables related to
interactions with others.
The most prevalent concerns were that the procedure
would be painful and that the donor’s family would worry
(>50% of donors for each concern). Groups differed
marginally on concern about potential damage to the donors’
health (BM ¼ 26% versus PBSC ¼ 39%). There were no group
differences in health concerns.
Although the majority of donors felt well informed (81%)
and fully prepared (80%), PBSC donors felt marginally less
prepared (BM ¼ 85% versus PBSC ¼ 75%) and were margin-
ally more likely to indicate that they needed more informa-
tion (BM¼ 20% versus PBSC¼ 30%). More than 90% of donors
were satisﬁed with the decision to donate and would
volunteer againdthere were no group differences in
satisfaction.
Characteristics Forty-eight Hours Post Donation
There were no differences in AE or SAE by donor type
(Table 3). BM donors reported lower overall physical health
at this time point. The most commonly reported donation-
related symptoms were tiredness and muscle aches, and
BM donors were signiﬁcantly more likely to report experi-
encing multiple current symptoms. Table 3 reports pain for
PBSC donors on day 4 of rhGCSF administration and for BM
donors within 48 hours post donation, as these are the time
points when the 2 groups are likely to experience the most
pain. BM donors’ worst pain was marginally higher than that
of PBSC donors, but the 2 groups did not differ on other pain
indicators. BM donors reported better overall psychological
status. There were no other group differences in psycholog-
ical status.
Two thirds of donors reported that the donation was
physically stressful and w60% reported that the donation
was emotionally stressful. More than half were worried
about longer term health effects, and approximately one
third were worried that they might never feel physically
100%. There were no group differences in these variables.
The most frequently endorsed social impacts of donation
were effects on leisure and/or recreation and work and/or
school. BM donors reported more impact on leisure and/or
recreation activities and a marginally greater need to make
child care arrangements. There were no other group differ-
ences in donation inconveniences.
The majority of donors were satisﬁed with the donation
decision and there were no group differences in these vari-
ables. BM donors were marginally more likely to report that
donation had made their lives more meaningful (BM ¼ 48%
versus PBSC ¼ 35%).
Weekly Assessments for the First Three Weeks Post
Donation
BM donors reported signiﬁcantly more symptoms
(P .001) in each of the ﬁrst 3 weeks after donation. Four key
Table 2
Predonation Comparison of Marrow and PBSC Donors
Study Variable Marrow (n ¼ 161) PBSC (n ¼ 170) Test Statistic (t or Odds Ratio) P Value
Sociodemographic
Age, mean (SD) 33.6 (9.18) 35.1 (10.29) 1.45 .148
Women 34 34 1.03 (.65-1.62) .912
Married 63 53 .67 (.43-1.04) .071
Bachelor’s degree 46 53 1.32 (.86-2.04) .204
Employed 93 91 1.32 (.59-2.97) .501
Race
Caucasian/White 86 83
Hispanic 6 8
African American 4 4
Asian American 1 2
Other 2 2
Physical Status
Overall physical status
SF-8 physical health, (SD) (29-68)* 56.47 (3.71) 55.86 (4.79) .78 .436
Current physical symptoms
Tiredness 49 52 1.10 (.70-1.74) .685
Muscle aches 17 24 1.54 (.86-2.74) .145
Problems sleeping 15 16 1.07 (.57-2.00) .845
Bone pain 6 8 1.49 (.59-3.76) .397
Light headedness 6 5 .85 (.32-2.27) .747
Difﬁculty walking 4 4 .97 (.30-3.07) .952
Bleeding 7 3 .37 (.11-1.21) .087
Nausea or vomiting 1 4 6.00 (.71-50.47) .062
Infection 3 0 .48 (.43-.55) .041y
Chills 2 2 .97 (.19-4.87) .966
Fainting 1 1 .97 (.06-15.60) .981
Current physical symptoms
Psychological Status
Overall psychological status
SF-8 mental health, mean (SD) (28-69) 55.68 (4.83) 55.12 (5.37) .94 .350
Proﬁle of mood states
Depression, mean (SD) (0-4) .10 (.29) .11 (.24) .28 .784
Vitality, mean (SD) (0-4) 2.40 (.82) 2.46 (.67) .60 .548
Confusion, mean (SD) (0-4) .23 (.34) .31 (.40) 2.04 .043y
Tension, mean (SD) (0-4) .44 (.51) .45 (.47) .11 .911
Anger, mean (SD) (0-4)) .22 (.38) .22 (.32) .06 .951
Fatigue, mean (SD) (0-4) .46 (.61) .55 (.62) 1.36 .174
Total distress, mean (SD) (0-24) 4.21 (1.91) 4.19 (1.91) .07 .941
Donation-related
Interaction with others
Consulted family/friends 58 56 1.08 (.68-1.72) .738
Consulted professionals 29 35 .75 (.46-1.22) .242
Encouraged to donate 26 30 .80 (.48-1.33) .390
Discouraged from donating 26 27 .91 (.54-1.53) .727
Medical concerns
Pain 58 55 .89 (.56-1.40) .604
Anesthesia 35 33 .91 (.56-1.48) .709
Damage health 26 39 1.81 (1.10-2.97) .018y
Use of needles 13 16 1.33 (.69-2.58) .391
Work/family concerns
Family will worry 56 49 .78 (.49-1.23) .286
Missing work/school 43 41 .92 (.58-1.46) .714
Reimbursement for missed work 19 19 1.00 (.56-1.80) .993
Missing family activities 15 15 1.06 (.56-2.02) .857
Child/family care 15 11 .66 (.33-1.32) .239
Other concerns
Patient’s chances are low 43 38 .83 (.52-1.33) .443
Payment for medical treatment 18 14 .74 (.40-1.38) .343
Transportation to donor center 14 12 .85 (.43-1.67) .629
Against religious beliefs 0 1 .51 (.45-.57) .164
Overall health concerns
Worry about longer term health impact of donation 63 66 1.13 (.70-1.82) .615
Worry will never feel physically 100% again 29 27 .89 (.54-1.49) .658
Preparation
Feel very well informed 84 79 .70 (.39-1.27) .239
Feel totally prepared 85 75 .55 (.31-.99) .045y
Need much more information 20 30 1.70 (.99-2.91) .051y
Satisfaction with donation decision
Extremely satisﬁed with decision 90 91 1.05 (.48-2.30) .894
Would deﬁnitely volunteer again 92 91 .80 (.35-1.82) .590
(Continued)
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Table 2
(Continued)
Study Variable Marrow (n ¼ 161) PBSC (n ¼ 170) Test Statistic (t or Odds Ratio) P Value
Clinical
Weight, mean (SD), kg 88.12 (18.64) 85.07 (17.33) 1.52 .128
Height, mean (SD), cm 174.48 (9.15) 173.92 (10.26) .52 .607
PBSC indicates peripheral blood stem cells.
Data presented are % unless otherwise indicated.
* Response range.
y P  .05.
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aches, and difﬁculty walkingdwere reported by BM donors
at signiﬁcantly higher levels (P .001) across each of the ﬁrst
3 weeks post donation (data not shown). Tiredness, light-
headedness, nausea, problems sleeping, and chills were re-
ported by BM donors at marginally higher rates (P  .05) in
the ﬁrst week after donation, but these differences dis-
appeared by the second week post donation.Characteristics Six Months Post Donation
There were no group differences in overall physical or
psychological status (Table 4). The most common current
symptoms were tiredness (45%) and muscle aches (22%). The
only marginally signiﬁcant symptom differences were
lightheadedness (BM¼ 6% versus PBSC¼ 1%) and painwhere
the needles entered (BM ¼ 6% versus PBSC ¼ 1%).
Forty percent of donors knew the health status of their
recipient and 84% said that they had a special bond with the
recipient. Fifteen percent of donors indicated that they
thought about the recipient more than once each day and
33%wereworried about the recipient’s health. Therewere no
group differences in recipient-related variables.
Eighty-one percent of donors had reached 3 consecutive
symptom-free weeks by 6 months post donation and there
were no group differences in recovery.Characteristics Twelve Months Post Donation
PBSC donors had marginally better physical health status
at this time point than the BM donors (Table 5). However,
this was due to 3 extreme outliers (SF-8 physical mean < 40)
in the BM group. When we compared the distributions with
extreme outliers removed (t ¼ 1.28; df ¼ 279; P ¼ .20) and
with Kruskal-Wallis nonparametric tests (P ¼ .29) there was
no signiﬁcant difference in overall physical health. All 3 BM
donors with very low physical status scores at 12 months
post donation were female, ages 32 to 46. One donor had
experienced an SAE but was fully recovered (deﬁned as 3
symptom-free weeks) by 6 months post donation. Both that
donor and a second donor had higher SF-8 physical health
summary scores at 6 months post donation than before
donation and then declines between 6 and 12 months post
donation. There was no obvious link between donation and
the lower physical scores at 12 months post donation.
The third donor reported ongoing painwhere the needles
entered, difﬁculty walking, problems sleeping, bone pain,
and muscle aches throughout the 52-week follow-up period
and was still reporting symptoms at 12 months. This donor
had consistently poorer physical health scores at 6 and
12 months post donation.
Overall, the most common symptoms were tiredness
(55% of all donors) and muscle aches (23% of all donors).
There were no signiﬁcant symptom differences. There were
no group differences in overall psychological status ordistress. Nearly half of donors remained concerned about the
longer term health effects of donation and 13% worried that
they might never feel physically 100%. There were no group
differences in these variables.
The majority of donors were extremely satisﬁed with
their decision to donate (91%), would donate again if asked
(86%), and would encourage others to donate (81%). There
were no group differences in satisfaction variables.
Forty-one percent of donors knew the health status of
their recipient. Eleven percent of donors indicated that they
thought about the recipient more than once per day, 77%
reported that they had a special bond with the recipient, and
30%wereworried about the recipient’s health. Therewere no
group differences in recipient-related variables.
Eighty-seven percent of donors had reached 3 consecu-
tive symptom-free weeks by 12 months post donation and
there were no group differences in recovery. Among the
group still reporting weekly symptoms at 12 months post
donation, the most commonly reported symptoms across the
entire postdonation period were tiredness (w85% of the
group consistently reported this symptom), muscle aches
(w50%), and problems sleeping (w40%).Longitudinal Comparisons of Physical/Mental Status and
Recovery
Mean values for the physical and mental status compo-
nents of the SF-8 health survey are presented in Figure 1.
Mixed models analyses indicated that there were main ef-
fect differences for donation type (physical: F ¼ 30.2,
df¼ 1589, P< .001; mental: F¼ 8.9, df¼ 1,058, P¼ .003) and
time (physical: F ¼ 678.8, df ¼ 3643, P < .001; mental:
F ¼ 291.7, df ¼ 3539, P < .001). In addition, there were sig-
niﬁcant donation type by time interactions for both physical
and mental status (physical: F ¼ 15.6, df ¼ 3643, P < .001;
mental: F ¼ 3.2, df ¼ 3539, P ¼ .023). Both groups experi-
enced declines in physical status immediately following
donation and then scores higher than baseline levels at 6
and 12 months. At 48 hours post donation, BM donors re-
ported poorer physical status and PBSC donors reported
poorer mental status. Figure 2 presents the Kaplan Meier
recovery curves for BM and PBSC donors. There was no
signiﬁcant group difference in recovery (log rank chi-
square ¼ 1.85, P ¼ .18).DISCUSSION
This investigation is 1 of the ﬁrst to systematically and
comprehensively examine HRQoL experiences of BM and
PBSC donors in the context of a Phase III randomized trial. A
central ﬁnding of this investigation is that there do not
appear to be longer term differences in the HRQoL experi-
ences of the vast majority of BM and PBSC donors.
The pattern of ﬁndings before donation indicate that
BM donors are slightly advantaged over PBSC donors in
Table 3
Forty-Eight Hours Post-donation Comparison of Marrow and PBSC Donors
Study Variable Marrow (n ¼ 131) PBSC (n ¼ 142) Test Statistic (t or Odds Ratio) P Value
Physical Status
Overall physical status
SF-8 physical health, mean (SD) (29-68)* 35.38 (9.75) 43.37 (9.75) 6.59 .000x
Current physical symptoms
Tiredness 92 92 .98 (.40-2.40) .972
Muscle aches 75 56 .42 (.25-.71) .421
Problems sleeping 50 39 .66 (.41-1.07) .091
Bone pain 58 60 1.09 (.67-1.77) .717
Light headedness 50 34 .50 (.31-.82) .006z
Pain where needles inserted 83 55 .25 (.14-.44) .000x
Difﬁculty walking 87 39 .10 (.05-.18) .000x
Bleeding 41 10 .16 (.08-.30) .000x
Nausea or vomiting 28 25 .86 (.51-1.48) .590
Infection 0 0 e e
Chills 20 9 .41 (.20-.83) .012y
Fainting 3 0 .47 (.42-.54) .036y
Current paink
Pain index, mean (SD) (0-10) 4.23 (1.86) 3.84 (1.94) 1.68 .094
Average pain, mean (SD) (0-10) 4.04 (1.98) 3.63 (2.00) 1.69 .093
Worst pain, mean (SD) (0-10) 5.55 (2.45) 4.80 (2.26) 2.60 .009z
Time with pain, mean (SD) (0-10) 4.77 (2.42) 4.57 (2.58) .66 .513
Interfered with sleep, mean (SD) (0-10) 2.53 (2.40) 2.35 (2.34) .62 .535
Psychological Status
Overall psychological status
SF-8 mental health, mean (SD) (28-69) 55.40 (7.24) 52.23 (6.24) 3.85 .000x
Proﬁle of mood states
Depression, mean (SD) (0-4) .10 (.42) .12 (.24) .61 .541
Vitality, mean (SD) (0-4) 1.23 (.93) 1.46 (.88) 2.12 .035y
Confusion, mean (SD) (0-4) .26 (.69) .25 (.42) .13 .900
Tension, mean (SD) (0-4) .46 (.69) .47 (.51) .19 .848
Anger, mean (SD) (0-4) .12 (.48) .14 (.25) .50 .615
Fatigue, mean (SD) (0-4) 1.31 (1.02) 1.23 (.91) .69 .491
Total distress, mean (SD) (0-24) 5.01 (2.75) 4.75 (2.28) .85 .396
Donation-related
Donation experience
Donation physically stressful 76 75 .91 (.53-1.59) .746
Donation emotionally stressful 55 58 1.12 (.69-1.81) .643
Health concerns
Worry about longer term health impact of donation 55 58 1.10 (.68-1.78) .695
Worry will never feel physically 100% again 27 32 1.30 (.75-2.13) .389
Social impact
Leisure/recreation affected 87 51 6.46 (3.52-11.86) .000x
Work/school affected 75 70 1.29 (.75-2.20) .359
Transportation arrangements 58 47 1.55 (.96-2.50) .073
Child care arrangements 28 16 2.04 (1.13-3.66) .016y
Financial arrangements 18 13 1.55 (.80-3.00) .197
Home care help 7 4 1.67 (.58-4.83) .338
Satisfaction with donation decision
Extremely satisﬁed with decision 92 92 .90 (.37-2.15) .804
Would deﬁnitely donate again 79 78 .94 (.53-1.68) .843
Would strongly encourage others 82 82 1.00 (.53-1.86) .992
Feel a lot like a better person 76 76 1.02 (.58-1.78) .958
Feel very proud 63 65 1.06 (.65-1.75) .806
Made life much more meaningful 48 35 .58 (.35-.94) .026y
Recipient-related
Know health status of recipient 7 10 .67 (.28-1.60) .365
Think about recipient  once/day 79 78 .92 (.52-1.65) .784
Have special bond with recipient 82 79 .80 (.43-1.46) .457
Very/pretty worried about recipient 66 61 .80 (.49-1.32) .385
Clinical
Adverse event 15 16 1.12 (.61-2.06) .705
Serious adverse event 6 2 .30 (.08-1.13) .061
PBSC indicates peripheral blood stem cells.
* Response range.
y P  .05.
z P  .01.
x P  .001.
k For PBSC donors, pain was assessed on the fourth day of rhGCSF administration. For BM donors, pain was assessed 48 hours post donation.
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concerns about the donation procedure, and higher levels
of preparedness for donation. Existing literature is mixed
on whether there are predonation psychological andpreparedness differences between BM and PBSC donors,
but when such differences have been founddeg, in pre-
donation anxietydthey have also favored BM donors
[23,24]. It is possible that donor center staff were more
Table 4
Six Months after Donation Comparison of Marrow and PBSC donors
Study Variable Marrow (n ¼ 141) PBSC (n ¼ 153) Test Statistic (t or Odds Ratio) P Value
Physical Status
Overall physical status
SF-8 physical health, mean (SD) (29-68)* 65.18 (4.51) 64.96 (3.85) .45 .651
Current physical symptoms
Tiredness 42 48 1.30 (.82-2.06) .262
Muscle aches 24 20 .80 (.46-1.39) .427
Problems sleeping 10 15 1.61 (.79-3.26) .187
Bone pain 9 5 .54 (.22-1.35) .184
Light headedness 6 1 .22 (.05-1.06) .039y
Pain where needles inserted 6 1 .12 (.01-.89) .013y
Difﬁculty walking 5 5 .92 (.31-2.69) .876
Bleeding 1 2 2.80 (.29-27.23) .355
Nausea or vomiting 1 3 1.87 (.34-10.35) .469
Infection 0 2 .52 (.46-.58) .095
Chills 0 1 .52 (.47-.58) .336
Fainting 0 0 - -
Current pain
Pain index, mean (SD) (0-10) .60 (1.38) .67 (1.23) .44 .663
Average pain, mean (SD) (0-10) .57 (1.38) .61 (1.17) .25 .802
Worst pain, mean (SD) (0-10) .87 (1.83) .95 (1.64) .41 .685
Time with pain, mean (SD) (0-10) .69 (1.58) .82 (1.66) .68 .500
Interfered with sleep, mean (SD) (0-10) .29 (1.12) .31 (.94) .15 .879
Psychological Status
Overall psychological status
SF-8 mental health, mean (SD) (28-69) 65.49 (5.81) 65.03 (5.98) .66 .510
Proﬁle of mood states
Depression, mean (SD) (0-4) .10 (.27) .11 (.25) .37 .716
Vitality, mean (SD) (0-4) 2.16 (1.01) 2.22 (.98) .59 .555
Confusion, mean (SD) (0-4) .26 (.42) .30 (.80) .44 .660
Tension, mean (SD) (0-4) .31 (.45) .36 (.83) .57 .566
Anger, mean (SD) (0-4) .19 (.37) .22 (.78) .42 .676
Fatigue, mean (SD) (0-4) .45 (.63) .23 (.95) .81 .417
Total distress, mean (SD) (0-24) 3.15 (2.24) 3.10 (2.01) .22 .826
Donation-related
Donation experience
Donation physically stressful 74 75 1.04 (.62-1.75) .883
Donation emotionally stressful 63 69 1.28 (.79-2.07) .319
Health concerns
Worry about longer term health impact of donation 41 51 1.51 (.95-2.40) .81
Worry will never feel physically 100% again 14 9 .65 (.31-1.35) .241
Satisfaction with donation decision
Extremely satisﬁed with decision 92 88 .70 (.32-1.51) .357
Would deﬁnitely donate again 87 84 .78 (.40-1.51) .461
Would strongly encourage others 82 78 .79 (.44-1.41) .426
Feel a lot like a better person 75 75 .97 (.57-1.64) .895
Feel very proud 56 62 1.27 (.80-2.03) .312
Made life much more meaningful 31 28 .86 (.52-1.42) .561
Recipient-related
Know health status of recipient 39 41 .93 (.58-1.48) .756
Think about recipient  once/day 16 14 .85 (.45-1.63) .631
Have special bond with recipient 83 84 1.09 (.59-2.03) .776
Very/pretty worried about recipient 35 31 .87 (.53-1.41) .563
Recovery
Recovered at 6 months 81 82 1.11 (.63-1.95) .720
PBSC indicates peripheral blood stem cells.
* Response range.
y P  .05.
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more likely to seek out donation-related information on
their own, given the more invasive nature of this HSC
collection procedure. It is also possible that the adminis-
tration of rhGCSF, for which the longer term risks are likely
to be low but at the time of this investigation had not been
fully examined in healthy donors, may have heightened
health-related concerns in the PBSC group. Regardless of
the source of these concerns among PBSC donors, a review
and potential revision of the predonation counseling pro-
cess for PBSC donors may be warranted to ensure that all
donors are fully informed about the donation and recovery
process.Findings from 48 hours post donation indicate that BM
donors had experienced more physical side effects and pain
within the past 48 hours although the pain proﬁles of BM
donors at 48 hours post donation and PBSC donors on day 4
of rhGCSF administration were generally similar. BM donors
also reported that the donation had a greater impact on their
social activities. Despite these ﬁndings, BM donors were
more likely to report better psychological status and that the
donation had made their lives more meaningful at this time
point. This ﬁnding may be due to the greater physical in-
tensity of the BM donation process leading to more positive
psychological outcomes shortly after donation. It is also
possible that those close to BM donors may have viewed the
Table 5
Twelve Months Post-donation Comparison of Marrow and PBSC Donors
Study Variable Marrow (n ¼ 137) PBSC (n ¼ 151) Test Statistic (t or Odds Ratio) P Value
Physical Status
Overall physical status
SF-8 physical health, mean (SD) (29-68)* 63.95 (6.41) 65.21 (3.91) 2.03 .043y
Current physical symptoms
Tiredness 53 56 1.16 (.73-1.85) .525
Muscle aches 25 22 .85 (.49-1.46) .552
Problems sleeping 19 21 1.15 (.64-2.05) .640
Bone pain 12 9 .72 (.34-1.53) .391
Light headedness 4 7 1.87 (.62-5.62) .257
Pain where needles inserted 5 0 .99 (.96-1.01) .742
Difﬁculty walking 11 5 .46 (.19-1.11) .077
Bleeding 2 0 .47 (.42-.53) .136
Nausea or vomiting 4 4 1.09 (.33-3.66) .886
Infection 4 3 .90 (.26-3.19) .876
Chills 2 2 .91 (.18-4.56) .904
Fainting 1 0 .48 (.42-.54) .293
Current pain
Pain index, mean (SD) (0-10) .97 (1.72) .88 (1.40) .48 .632
Average pain, mean (SD) (0-10) .86 (1.60) .84 (1.43) .11 .910
Worst pain, mean (SD) (0-10) 1.24 (2.08) 1.28 (2.01) .18 .855
Time with pain, mean (SD) (0-10) 1.19 (2.12) 1.01 (1.72) .81 .420
Interfered with sleep, mean (SD) (0-10) .59 (1.64) .40 (1.16) 1.17 .245
Psychological Status
Overall psychological status
SF-8 mental health, mean (SD) (28-69) 64.94 (6.16) 64.86 (6.18) .11 .916
Proﬁle of mood states
Depression, mean (SD) (0-4) .11 (.28) .11 (.29) .11 .912
Vitality, mean (SD) (0-4) 2.19 (.99) 2.19 (.86) .02 .986
Confusion, mean (SD) (0-4) .28 (.40) .25 (.39) .61 .545
Tension, mean (SD) (0-4) .36 (.45) .34 (.48) .22 .828
Anger, mean (SD) (0-4) .19 (.32) .18 (.36) .40 .691
Fatigue, mean (SD) (0-4) .51 (.71) .55 (.71) .45 .657
Total distress, mean (SD) (0-24) 3.26 (2.38) 3.24 (2.27) .08 .940
Donation-related
Donation experience
Donation physically stressful 66 68 1.05 (.64-1.72) .839
Donation emotionally stressful 60 58 .94 (.59-1.50) .786
Health concerns
Worry about longer term health impact of donation 43 50 1.30 (.82-2.08) .264
Worry will never feel physically 100% again 17 10 .55 (.27-1.10) .086
Satisfaction with donation decision
Extremely satisﬁed with decision 91 91 1.03 (.45-2.34) .949
Would deﬁnitely donate again 88 85 .74 (.37-1.46) .379
Would strongly encourage others 79 82 1.23 (.69-2.21) .481
Feel a lot like a better person 72 71 .94 (.56-1.58) .823
Feel very proud 66 58 .71 (.44-1.14) .155
Made life much more meaningful 31 29 .93 (.56-1.54) .779
Recipient-related
Know health status of recipient 43 40 1.14 (.71-1.82) .598
Think about recipient  once/day 10 11 1.05 (.49-2.24) .901
Have special bond with recipient 78 77 .96 (.55-1.67) .876
Very/pretty worried about recipient 34 26 .69 (.41-1.16) .160
Recovery
Recovered at 12 months 87 87 .95 (.50-1.82) .876
PBSC indicates peripheral blood stem cells.
* Response range.
y P  .05.
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therefore, have been more engaged with and congratulatory
of the donor. Differences in physical side effects persisted for
at least 3 weeks post donation, with BM donors experiencing
signiﬁcantly greater adverse effects in these areas than PBSC
donors.
There were few longer term differences in the experi-
ences of the 2 donor groups. At 6 months post donation, BM
donors were slightly more likely to report continued light-
headedness and pain where the needles entered than were
PBSC donors, and at 12 months, BM donors reported
marginally poorer physical status. However, the former re-
sults are not statistically signiﬁcant after correcting formultiple comparisons, and the latter was entirely due to 3
outliers in the BM groupwith very low physical status scores.
For 2 of these outliers, there was no apparent link between
donation and the lower 12-month physical scores. The third
donor reported ongoing symptoms in addition to lower 6-
and 12-month physical scores.
Nearly half of donors overall had at least some lingering
concerns about the longer term health impact of donation at
12 months post donation. It is possible that this is a natural
side effect of any important nonrequired medical procedure,
but it suggests that predonation information sessions and
postdonation follow-up could better emphasize the very low
probability that BM or PBSC donation will have longer term
Figure 1. Longitudinal pre- and postdonation physical and mental states for
bone marrow and peripheral blood stem cell donors. Physical and mental
health summary scores were assessed with the Short Forme8; higher scores
indicate better physical or mental health.
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dations from the World Marrow Donor Association about
longer term donor follow-up, these residual health concernsFigure 2. Time to full recoveshould be the subject of ongoing assessment beyond the ﬁrst
year post donation [25].
Longitudinal group differences in physical and psycho-
logical status were the result of declines in physical statusd
and psychological status for PBSC donorsdimmediately
following donation, but then gains to levels above predona-
tion levels at 6 and 12 months post donation. Longitudinal
group by time physical and psychological status interactions
were primarily due to 48-hour postdonation differences
when BM donors reported poorer physical status but better
psychological status than did PBSC donors. There was no
recovery time difference between the 2 groups as assessed
starting 3 weeks post donation, the ﬁrst point at which a
donor could be recorded as fully recovered.
It is interesting that approximately 13% of donors had not
met our deﬁnition of recovery by 12 months post donation.
This is likely partly a result of our conservative deﬁnition of
recoveryd3 consecutive symptom-free weeks and assess-
ment of all symptoms, regardless of whether they were
attributable to donationdbut may also indicate that there
are other interesting characteristics about this subgroup. The
most commonly reported symptoms by this group were
fatigue, muscle aches, and problems sleeping, which are
less likely to be an ongoing result of donation than some
other symptoms. We are currently analyzing predictors of
recoverydincluding predonation physical and psychological
statusdfor a separate manuscript. Other investigations that
asked donors speciﬁcally about their recovery from the
donation process, rather than reporting all symptoms
regardless of whether they are attributable to donation, ﬁnd
that the majority of donors report feeling recovered withinry by product donated.
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6 months post donation [26].
Overall, these ﬁndings suggest that although BM donors
may experience the process as more physically uncomfort-
able in the short term, the physical impact of donation re-
solves relatively quickly and there are few longer term
differences, in aggregate, between the 2 groups. Conversely,
BM donors may experience greater short-term psychological
gains from donation, particularly in terms of feeling like the
donation made their lives more meaningful, but there are no
longer term differences between the 2 groups in terms of
psychological beneﬁt.
A key limitation of the investigation is that donors were
primarily white, and all were required to be able to write,
read, and speak English. Given the randomized study design
and inclusion criteria, this was expected. However, it may
limit generalizability to broader groups of donors. In addi-
tion, all participants were unrelated donors belonging to the
NMDP registry. Their characteristicsdyoung, self-selected,
knowledgeable, healthy, and highly motivateddmay make
it difﬁcult to extrapolate these ﬁndings to other groups of
donors, particularly related donors. We are currently con-
ducting an NIH-funded investigation that will compare the
HRQoL experiences of donors who are related to the recip-
ient and those who are unrelated.
Despite these limitations, this investigation improves our
understanding of HRQoL issues involved in the HSC donation
process, provides a stringent comparison of these 2 methods
of donation, and indicates that the longer term HRQoL con-
sequences of BM and PBSC donation are similar in the vast
majority of donors.
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